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KinaseAs with the majority of G-protein-coupled receptors, all four of the adenosine receptor subtypes are known to
undergo agonist-induced regulation in the form of desensitization and trafﬁcking. These processes can limit
the ability of adenosine receptors to couple to intracellular signalling pathways and thus reduce the ability of
adenosine receptor agonists as well as endogenous adenosine to produce cellular responses. In addition, since
adenosine receptors couple to multiple signalling pathways, these pathways may desensitize differentially,
while the desensitization of one pathway could even trigger signalling via another. Thus, the overall picture of
adenosine receptor regulation can be complex. For all adenosine receptor subtypes, there is evidence to
implicate arrestins in agonist-induced desensitization and trafﬁcking, but there is also evidence for other
possible forms of regulation, including second messenger-dependent kinase regulation, heterologous effects
involving G proteins, and the involvement of non-clathrin trafﬁcking pathways such as caveolae. In this
review, the evidence implicating these mechanisms is summarized for each adenosine receptor subtype, and
we also discuss those issues of adenosine receptor regulation that remain to be resolved as well as likely
directions for future research in this ﬁeld. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
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All four adenosine receptor subtypes undergo agonist-induced
desensitization and trafﬁcking, but with somewhat different time
frames and possibly distinct mechanisms [1]. It is important to
identify and characterize these mechanisms, since not only could
these processes modify the response to agonists in a therapeutic
setting, but they could also modify responsiveness to the endogenous
agonist adenosine, whose concentration in tissues varies under
various physiological and pathological conditions [2–4]. Thus, changes
in adenosine receptor function are likely to have important con-sequences for the organism. However, before discussing data relating
to the characteristics and mechanisms of regulation of the adenosine
receptors, it is necessary to provide a general introduction to the
desensitization and trafﬁcking of G-protein-coupled receptors. Fol-
lowing this, the regulation of each adenosine receptor subtype will be
described in turn.2. G-protein-coupled receptor regulation
G-protein-coupled receptor function is tightly regulated. Follow-
ing the prolonged or repeated exposure to agonist ligands receptors
can desensitize, leading to a loss of drug responsiveness [5]. The
nature of this desensitization can be homologous or heterologous. In
homologous desensitization, only the responsiveness to the receptor
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locus of the regulatory change that leads to desensitization.
Heterologous desensitization involves a more generalized loss of
cellular responsiveness where the responsiveness of multiple recep-
tors, including those not activated by the agonist, is lost. This type of
desensitization can involve changes downstream of the receptor such
as the G protein or effector enzyme or the phosphorylation of receptor
by second messenger-dependent protein kinases. In many cases,
receptor phosphorylation is the critical event in G-protein-coupled
receptor desensitization. For homologous desensitization, a common
mechanism involves the phosphorylation of agonist-occupied G-
protein-coupled receptors by a family of kinases, the G-protein-
coupled receptor kinases (GRKs) [6–8]. These kinases usually
phosphorylate serine or threonine residues in the third intracellular
loop or COOH-terminus of the receptor, leading to the binding of
another class of proteins, the arrestins, to the GRK-phosphorylated
receptor [9,10] (Fig. 1). Although GRK phosphorylation is undoubt-
edly a major trigger for arrestin association with most G-protein-
coupled receptors, for some receptors the agonist-induced change in
receptor conformation can also lead to arrestin interaction. For
example, arrestin association with the lutropin (hLHR) and leukotri-
ene B receptor is phosphorylation independent [11,12]. Arrestin
binding desensitizes receptor responsiveness by uncoupling receptor
from G protein [9,10]. However, apart from effecting desensitization
of signalling pathways dependent upon G protein activation, the
arrestins are also able to initiate alternative signalling pathways in the
cell by interacting with multiple signalling proteins [13] such as those
that lead to activation of themitogen-activated protein (MAP) kinases
[14].
G-protein-coupled receptor responsiveness can also be up-
regulated or sensitized [15]. Receptor sensitization can involve
various changes including increases in cell surface receptor number,
enhanced coupling to effector enzyme, or an increase in effector
enzyme activity or amount. Sensitization of G-protein-coupled
receptor responses can be triggered by the ability of various cellular
factors or drugs to increase receptor number at the cell surface, for
example by the ability of antagonist ligands to act as “pharmacocha-
perones”, thus causing receptors to accumulate at the cell surface
[16,17]. Sensitization can also be caused by the ability of antagonistFig. 1. Homologous desensitization and trafﬁcking of G-protein-coupled receptors
mediated by GRKs and arrestins. The GPCR is activated by agonist (1) leading to G
protein coupling (2) and effector modulation. The agonist-occupied GPCR is
subsequently phosphorylated by GRK (3) and arrestin binds to the phosphorylated
GPCR, leading to receptor desensitization (4) and internalization to endosomes (5). For
most GPCRs, internalization following relatively short-term agonist treatment leads to
dephosphorylation (6) and recycling (7) of the GPCR. Depending upon the GPCR
subtype, arrestin either dissociates from the receptor at the plasma membrane or after
co-internalization with the receptor (5). Particularly with longer agonist treatments,
internalized GPCR may also be targeted for down-regulation (8). Newly synthesized
receptor, or receptor stored in an intracellular pool, can also be inserted into the plasma
membrane (9), although the factors that control this are poorly understood.ligands to block the tonic desensitizing effects of endogenous agonist
acting at the receptor or by the ability of inverse agonists at these
receptors to suppress the constitutive activity of some G-protein-
coupled receptors [18].
In most studies, trafﬁcking usually refers to the internalization of
the G-protein-coupled receptor, but trafﬁcking also covers other types
of receptor movement within the cell including recycling, insertion of
new receptor into the plasma membrane, and the sorting of
internalized receptors to lysosomes for proteolytic degradation
[19,20] (Fig. 1). The most common mechanism of agonist-induced
G-protein-coupled receptor internalization involves the arrestin-
dependent targeting of receptors to clathrin-coated pits, which
leads to the formation of clathrin-coated vesicles as the receptor
internalizes and eventually appear in endosomes, from where sorting
for recycling or degradation can occur [19,20]. In endosomes, G-
protein-coupled receptors can be dephosphorylated and arrestins can
dissociate so that the receptor can be recycled back to the cell surface
to reinstate agonist responsiveness. Other important G-protein-
coupled receptor trafﬁcking pathways include caveolae and lipid
rafts [21,22], which contain high concentrations of cholesterol and
glycosphingolipids. There is also good evidence to indicate that
caveolae/lipid rafts are key domains for cell signalling since some
receptors and signalling proteins are concentrated in these regions
[21,22]. Caveolae have also been shown to be crucial for A1 adenosine
receptor signalling [23].
G-protein-coupled receptor down-regulation, which is deﬁned as
the loss of receptor from the cell, is another important component of
receptor regulation [5]. Down-regulation is particularly important
when considering the long-term effects of agonists and is often
overlooked in desensitization studies where the focus is normally on
the mechanism of acute desensitization over minutes as opposed to
hours. Down-regulation of most G-protein-coupled receptors nor-
mally occurs in response to treatment with agonist for hours or longer
and usually involves the lysosomal degradation of the receptor. The
molecular signals that determine G-protein-coupled receptor down-
regulation versus recycling are still poorly understood [19,20].
3. Adenosine receptor desensitization and trafﬁcking
The desensitization and trafﬁcking of adenosine receptor subtypes
has already been the subject of a number of reviews over the years
[24–27], and indeed relatively recently there has been a comprehen-
sive review of this area [1]. It is therefore not the aim of this review to
detail all the work that has been produced in this expanding ﬁeld, but
instead to summarize the major ﬁndings, to discuss areas where there
is conﬂicting data, to highlight recent advances, and to discuss
important questions for future research. As the molecular details of G-
protein-coupled receptor regulation become clearer, a striking theme
is not the uniformity of G-protein-coupled receptor regulation but
instead the diversity of regulatory mechanisms that these receptors
are subject to [28]. This important point need to be borne in mind
when considering the desensitization and trafﬁcking of adenosine
receptor subtypes.
3.1. A1 adenosine receptor desensitization and trafﬁcking
The agonist-induced desensitization of the Gi-coupled A1 adeno-
sine receptor has been demonstrated for endogenous receptors in
adipocytes [29,30] and brain [31–36] as well as in cell lines derived
from smooth muscle [37–40] and thyroid cells [41] and receptors
heterologously expressed in CHO cells [42]. In some cases, the
desensitization appears to develop quite slowly, requiring hours of
agonist treatment [37], with little or no agonist-induced A1 adenosine
receptor phosphorylation, even in the presence of exogenous GRK2
[42], and only limited observable arrestin translocation [43]. In other
studies, the rapid (minutes) desensitization of A1 adenosine receptor
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receptors can also couple to this pathway) as well as the rapid
phosphorylation of serine and tyrosine residues in the receptor [39].
Other data suggest that changes in G protein expression may also
contribute to the desensitization of A1 adenosine receptor respon-
siveness [29,30]. Analysis of the A1 adenosine receptor indicates that
the COOH-terminus of the receptor contains a single threonine
residue but no serine or tyrosine residues, although there is a cluster
of serine residues in the third intracellular loop (SASS; Fig. 2).
Whether or not the third intracellular loop is a site for GRK
phosphorylation remains to be determined, while the phosphoryla-
tion of tyrosine residues in G-protein-coupled receptors has recently
been implicated in modulating receptor coupling [44]. The A1
adenosine receptor can be phosphorylated (this time on serine and
threonine residues) and desensitized following activation of the
second messenger-dependent protein kinases A or C [39], indicating
that this receptor can also be regulated heterologously. Recent data
also strongly suggest that the A1 adenosine receptor is regulated by
arrestins. In DDT1 MF-2 smooth muscle cells, agonist addition for as
little as 2 min increased arrestin-2 association with the plasma
membrane, while knockdown of arrestin-2 with siRNA almost
completely reversed agonist-induced down-regulation of A1 adeno-
sine receptor as assessed by the loss of agonist binding to the cells
[40]. Since the arrestin-2 knockdown also blocked agonist-induced
MAP kinase activation, it remains unclear whether the down-
regulation of A1 adenosine receptors is due directly to loss of arrestin
association with the receptor or is subsequent to the loss of arrestin-
dependent activation of MAP kinase [40].
The reason for some of the variations in reported kinetics of
desensitization between studies is not clear, but even in the same cell
types, differences in the rate of A1 adenosine receptor desensitization
have been reported, with rapid desensitization of postsynaptic A1
adenosine receptors and slow desensitization of presynaptic A1
adenosine receptors being observed in cultured hippocampal neu-
rones [34]. Thus, although the A1 adenosine receptor undoubtedly
undergoes agonist-induced desensitization, there are still questions
regarding the kinetics of desensitization and the mechanism/s
involved. It is possible that much of this disparity is due to factorsFig. 2. Comparison of the predicted intracellular (ﬁrst, second, and third intracellular
loops, and COOH-terminus) sequences of the rat and human A1 adenosine receptors
(UniProtKB/Swiss-Prot accession numbers P25099 and P30542, respectively) obtained
from http://www.uniprot.org/. All serine and threonine residues are shown in bold, while
potential phosphorylationsitespredictedbyNetPhos (i.e., scoreN0.5;http://www.cbs.dtu.dk/
services/NetPhos/) are also underlined. The amino acids in green italics show part of the
predicted caveolin interaction domain present in the receptor, with the beginning of the
sequence being just inside the 7th transmembrane domain of the receptor. The full sequence
in the human receptor is YAFRIQKF, which corresponds to the caveolin interaction sequence
ϕXϕXXXXϕ, where ϕ is a hydrophobic amino acid (ϕXXXXϕXϕ is an alternative caveolin
interaction sequence).such as cell context, or the extent of receptor reserve for different
cellular responses such as adenylyl cyclase inhibition and inositol
phosphate generation, as it is often more difﬁcult to observe agonist-
induced desensitization for responses with a large receptor reserve
than a small receptor reserve. On the whole, however, it would seem
that the rate of agonist-induced desensitization of A1 adenosine
receptor responsiveness is somewhat slower than that observed for
the other adenosine receptor subtypes described below.
A1 adenosine receptors internalize rather slowly (t0.5 for internal-
ization can be hours) relative to other adenosine receptor subtypes
[45–47]. There is convincing data to implicate caveolae in this process
[22] since in DDT1 MF-2 cells A1 adenosine receptors still undergo
agonist-induced internalization in the presence of inhibitors of
clathrin-mediated internalization [22]. The A1 adenosine receptor
contains a caveolin binding domain at the junction of the seventh
transmembrane domain and the COOH-terminus tail (see legend to
Fig. 2). Interestingly, the other adenosine receptor subtypes also
contain this motif at the same location (see Figs. 3, 5, and 6), and there
is some evidence that the A2A and A2B adenosine receptors may in part
reside in caveolae/lipid rafts [48–50]. In addition to caveolae, A1
adenosine receptors may also internalize via clathrin-coated vesicles
in brain [31], also suggested by the recent study implicating arrestin-2
in A1 adenosine receptor down-regulation [40]. Although A1 adeno-
sine receptor internalization is slow, agonist-induced clustering of
receptors at the cell surface of DDT1 MF-2 cells occurs quite rapidly,
within minutes [39]. However, whether this relates to receptor
trafﬁcking in caveolae, to a weak interaction with arrestins, or some
other factor, is not clear.
Adenosine deaminase, the enzyme that deaminates adenosine to
inosine, has been recognized as an A1 adenosine receptor-interacting
protein [51,52]. In the presence of agonist, adenosine deaminase
interacts with the extracellular loops of the receptor and is
internalized with the receptor [45]. Adenosine deaminase appears
to enhance the rate of A1 adenosine receptor regulation, with
increased rates of agonist-induced phosphorylation, desensitization,
and internalization [45]. Other A1 adenosine receptor-interacting
proteins include Heat shock cognate protein 73 [53] and Protein 4.1G
[54], which may affect A1 adenosine receptor distribution and
function in the cell [52]. Indeed another heat shock family protein
member, D1 receptor-interacting protein 78, was very recently
reported [17] to interact directly with the A1 adenosine receptor
and to prevent its export from the endoplasmic reticulum of the cell,
so reducing receptor levels at the plasma membrane.
In summary, there is now good evidence for arrestin-dependent
regulation of the A1 adenosine receptor [40] but also evidence for the
involvement of other regulatory pathways which may not involve
arrestins, including secondmessenger-dependent receptor regulation
[39], heterologous effects via changes in G protein expression [29,30],
and the involvement of caveolae/lipid rafts in trafﬁcking [22]. It is
possible that unlike the other adenosine receptor subtypes, the rate of
phosphorylation and consequent arrestin binding to the A1 adenosine
receptor is relatively slow, which facilitates other types of regulation,
e.g., caveolae-dependent internalization. However, it is clear that
further molecular studies on the trafﬁcking of the A1 adenosine
receptor and in particular the involvement of caveolae/lipid rafts
versus arrestin/clathrin in different cell types would be helpful. In
addition, the identiﬁcation of A1 adenosine receptor residues
phosphorylated by G-protein-coupled receptor kinases or second
messenger-dependent protein kinases would greatly help further
progress in understanding the regulation of this receptor.
3.2. A2A adenosine receptor desensitization and trafﬁcking
The agonist-induced desensitization of the Gs-coupled A2A aden-
osine receptor has been demonstrated both in cell lines [37,55–62] as
well as in intact tissues [63–65], in many cases measured as a
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adenylyl cyclase activation. Signiﬁcant evidence indicates that
desensitization of the A2A adenosine receptor response is mediated
by a GRK- and arrestin-dependent process. For example, in NG108-15
rat neuroblastoma X mouse glioma cells that express A2A adenosine
receptors endogenously, manipulations that enhance or decrease the
activities of GRKs/arrestins can in turn enhance or decrease the rate or
extent of agonist-induced A2A adenosine receptor desensitization
[58,60,61]. Furthermore, agonist treatment of A2A adenosine receptor-
expressing human monocytoid THP-1 cells increased the association
of GRK2 with the plasma membrane and induced desensitization of
A2A adenosine receptor responsiveness; tumor necrosis factor α
(TNFα) treatment of the cells prevented the translocation of GRK2 as
well as the desensitization of the A2A adenosine receptors [62]. Also in
HEK293 cells transfected with A2A adenosine receptors, the selective
agonist CGS21680 induced the translocation of non-visual arrestins to
the plasma membrane [66]. For the canine A2A adenosine receptor,
Thr298 in the proximal region of the COOH-terminus of the receptor
(equivalent to Thr293 and Thr298 in the rat and human receptors,
respectively; Fig. 3) was shown to be critical for the agonist-induced
phosphorylation and acute desensitization of the receptor; this
residue possibly acting as a phosphoacceptor for GRKs [57]. On the
other hand for longer term regulation, this mutant receptor still
down-regulated to a similar extent as the wild-type receptor [57].
Apart from GRK-/arrestin-dependent regulation, heterologous effects
have also been reported following prolonged activation of the A2A
adenosine receptor, including changes in the expression levels of G
protein subunits [55] as well as changes in adenylyl cyclase enzyme
function [67] and phosphodiesterase activity [68]. In addition, PKC-
mediated phosphorylation of the A2A adenosine receptor has beenFig. 3. Comparison of the predicted intracellular sequences of the rat and human A2A
adenosine receptors (UniProtKB/Swiss-Prot accession numbers P30543 and P29274,
respectively). All serine and threonine residues are shown in bold, while potential
phosphorylation sites predicted by NetPhos (score N0.5) are also underlined. The
threonine residues marked in red are equivalent to the threonine residue (Thr298) in
the canine sequence, which has been shown to be important for agonist-induced
phosphorylation and desensitization of that receptor. The sequence in blue italics is the
YXXGϕmotif, which may interact with AP-2 protein in clathrin-coated pits. The amino
acids in green show part of the predicted caveolin interaction domain present in the
receptor, with the beginning of the sequence being just inside the 7th transmembrane
domain of the receptor. The full sequence in the rat and human receptors is YAYRIREF,
which corresponds to the caveolin interaction sequence ϕXϕXXXXϕ.reported, although not at Thr298, and furthermore this did not
apparently affect receptor signalling or internalization [69].
There is also evidence that the A2A adenosine receptor is resistant
to desensitization in PC12 cells and striatal neurons, at least over a 30-
min agonist treatment period, although the high level of A2A receptor
expression (1 pmol/mg protein or more) and probable large receptor
reserve in these cell types may have made it difﬁcult to measure rapid
desensitization [49]. Certainly in PC12 cells the desensitization of A2A
adenosine receptor responsiveness does occur with longer agonist
incubation [55]. Of interest, we have found that in CHO cells stably
expressing the rat A2A adenosine receptor, the agonist-induced
(10 μM NECA for N2 h) desensitization of A2A adenosine receptor-
stimulated cyclic AMP is modest and sometimes difﬁcult to detect
(Matharu and Kelly, unpublished observations).
The agonist-induced internalization of A2A adenosine receptors
has been demonstrated in cultured cells [48,66,70–72]. The internal-
ization appears to be arrestin dependent [66], and in NG108-15 cells
at least, internalization does not contribute to desensitization, but
rather blockade of internalization inhibits resensitization [73]. This
again suggests that in this cell type at least, A2A adenosine receptor
internalization is mediated by the classical GRK/arrestin mechanism.
Furthermore, the COOH-terminus of the A2A adenosine receptor
contains the YXXGϕmotif (Fig. 3; YTLGL in rat and YALGL in human; X
is any amino acid and ϕ is a bulky hydrophobic residue), which can
bind to the AP-2 protein, a component of clathrin-coated pits [19,74],
further suggesting the likelihood of clathrin-dependent internaliza-
tion of this receptor. However, as with desensitization, there are some
suggestions that the A2A adenosine receptor is resistant to agonist-
induced internalization [49,75], but this has to be weighed against
studies that report signiﬁcant agonist-induced internalization of this
receptor [48,66,70–72]. This could in part be due to the constitutive
activity displayed by the A2A adenosine receptor [76], which may lead
to internalization in the absence of agonist, thus making it more
difﬁcult to observe agonist-induced internalization. Our own studies
(Mundell, Matharu, and Kelly, unpublished observations) have shown
that in CHO cells stably transfected with the rat A2A adenosine
receptor, the receptor undergoes rapid and extensive agonist-induced
internalization (Fig. 4); intriguingly, these are the same cells where
we ﬁnd it difﬁcult to readily detect desensitization. Furthermore,
deletion of the distal ten amino acids (Ser401 onwards) of the rat
receptor's COOH-terminus blocks agonist-induced internalization, at
least in the short term (Fig. 4). This suggests that the distal region of
the COOH-terminus of the receptor is important for the arrestin
interaction, and indeed in the rat receptor ﬁve of the last ten aminoFig. 4. Agonist-induced cell surface loss of the rat A2A adenosine receptor stably
expressed in CHO cells. An ELISA assay was used to quantify cell surface loss of the
receptor tagged at the NH2-terminus with an HA epitope [86]. The assay was
undertaken exactly as described for the A2B adenosine receptor [88]. The agonist was
NECA (10 μM). A deletion mutant, A2A 400 stop, with the distal COOH-terminus of the
rat receptor missing (SSWSSEFAPS), was resistant to agonist-induced internalization.
Values are means±SEM from 3 independent experiments.
Fig. 5. Comparison of the predicted intracellular sequences of the rat and human A2B
adenosine receptors (UniProtKB/Swiss-Prot accession numbers P29276 and P29275,
respectively). All serine and threonine residues are shown in bold, while potential
phosphorylation sites predicted by NetPhos (score N0.5) are also underlined. The
residues shown in red italics indicate the type II PDZ ligand (X-ϕ-X-ϕ) present at the
COOH-terminus of the receptor. The amino acids in green show part of the predicted
caveolin interaction domain present in the receptor, with the beginning of the sequence
being just inside the 7th transmembrane domain of the receptor. The full sequence in
the rat and human receptors is YAYRNRDF, which corresponds to the caveolin
interaction sequence ϕXϕXXXXϕ.
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phosphorylation sites (Fig. 3). However, as noted above, for the canine
receptor Thr298, in the proximal portion of the COOH-tail, was
identiﬁed as a crucial residue with regard to rapid desensitization
[57]. It is possible that desensitization and internalization of the A2A
adenosine receptor require different regions of the receptor's COOH-
terminus; however, it is notable that while the rat A2A adenosine
receptor has ﬁve serine residues in the distal COOH-terminus, the
human receptor has a single serine residue (Fig. 3), and the canine
receptor has no phosphoacceptor sites in the distal COOH-terminus
[57]. Thus, the regulation of the A2A adenosine receptor may be
species dependent, although further study would be required to
conﬁrm this.
Antagonist treatment has also been reported to alter A2A
adenosine receptor function; incubation of porcine coronary artery
with the antagonist ZM 241385 for 3 h led to A2A adenosine receptor
desensitization, but with an increase in A2A receptor expression and a
reduction in Gs expression [77]. The mechanism underlying these
changes was not resolved, but it is interesting to note that ZM 241385
is actually an inverse agonist at this receptor [78] and prolonged
treatment could potentially exert novel regulatory effects.
Both structurally and functionally, the A2A adenosine receptor is
somewhat different from the other adenosine receptor subtypes,
having a particularly long COOH-terminus which is reported to
interact with a number of proteins [49,75] that could regulate
receptor signalling and trafﬁcking, including α-actinin [66], ubiqui-
tin-speciﬁc protease 4 (USP4) [79], and neuronal calcium-binding
protein 2 (NECAB) [80]. These interactions can regulate A2A adenosine
receptor number at the cell surface [52]. In addition, it has been
suggested that the mode of coupling of the A2A adenosine receptor to
G protein is different from the other adenosine receptor subtypes,
with the receptor forming a tight interaction with G protein, referred
to variously as “restricted collision coupling” or “precoupling” [49,75].
This appears to restrict agonist-induced movement of the receptor in
the cell membrane due to the location of the receptor in a cholesterol-
rich region of the membrane, probably caveolae/lipid rafts, rather
than by attachment to the actin cytoskeleton [49]. The evidence for
the properties of the A2A adenosine receptor that differentiate it from
the other adenosine receptor subtypes has been detailed in a recent
review [75], and it is possible that these distinct properties explain the
reported difﬁculties in observing agonist-induced desensitization and
internalization of the receptor in some cell types. For example, the
binding of interacting proteins [49,75] to the COOH-terminus of the
A2A adenosine receptor could either stabilize the receptor at the cell
surface or inhibit the interaction of GRKs or arrestins with the
receptor.
One further issue of interest with regard to the A2A adenosine
receptor is its apparent ability to form heterodimers with D2
dopamine receptors [81]. Agonist treatment can induce co-desensi-
tization and co-internalization of these receptors [48,70,71], and there
are complex interactions between these receptors [82] such as
dopamine agonist-induced sensitization of A2A adenosine responses
[15] and A2A adenosine receptor antagonist-induced increases in D2
dopamine receptor function [83]. In the brain, particularly in the
striatum, such interactions are thought to be of considerable
importance and may underlie the beneﬁcial effects of A2A adenosine
receptor antagonists in Parkinson's disease and other neurodegener-
ative disorders [3,4].
3.3. A2B adenosine receptor desensitization and trafﬁcking
As with the A2A adenosine receptor, the agonist-induced desen-
sitization of the Gs-coupled A2B adenosine receptor has been
demonstrated in both cell lines [50,58,59,84–88] and intact tissues
[89,90]. Desensitization is in the main relatively rapid (t0.5 often less
than 1 h) and extensive, and in NG108-15 cells or HEK293 cells thateach natively express A2B adenosine receptors, manipulations that
enhance or decrease the activities of GRKs/arrestins can in turn
enhance or decrease the rate or extent of agonist-induced A2B
adenosine receptor desensitization [58,85]. The lack of effect of PKA
or PKC inhibition on agonist-induced desensitization of A2B adenosine
receptors [84] appears to rule out an involvement of these second
messenger-dependent kinases in agonist-induced homologous regu-
lation of this adenosine receptor subtype.
Although there appears to be a strong case for A2B adenosine
receptor desensitization by the classical GRK/arrestin mechanism,
there are data available to suggest that regulation may not be so
straightforward. In human airway smooth muscle cells, desensitiza-
tion of the A2B adenosine receptor does not appear to be modiﬁed
following reductions in the levels or activity of GRK2/3 [91], whereas
in our own studies in CHO or HEK293 cells, we were unable to detect
agonist-induced A2B adenosine receptor phosphorylation even in the
presence of overexpressed GRK2 [88]. Furthermore, we found that
although removal of the SLSL sequence at the end of the rat receptor's
COOH-terminus (Fig. 5) inhibited agonist-induced arrestin transloca-
tion and rapid receptor desensitization, replacement with the
equivalent amino acids from the human sequence (GVGL) reinstated
arrestin recruitment [86,88], and rapid desensitization. Thus, although
we had previously suggested [86] that GRKs could phosphorylate
serine residues in the SLSL sequence, these results demonstrate that
phosphorylation in this region of the receptor is probably not critical
for receptor regulation. Indeed, we have suggested that arrestin may
even interact with the receptor in a phosphorylation-independent
manner [88], as has been shown for other G-protein-coupled
receptors [11,12]. However, phosphorylation of threonine residues
in the receptor endogenously expressed in human astroglial cells has
been reported [87,92], so it is clear that further work will be required
before this issue is resolved. Analysis of the intracellular regions of the
rat and human A2B adenosine receptor indicates that there are
possible phosphoacceptor sites (Fig. 5), but a systematic analysis of
A2B adenosine receptor phosphorylation has not been carried out.
In most cases, A2B adenosine receptor desensitization appears to
be homologous [84], but the A2B adenosine receptor itself may be a
target for heterologous regulation; in human astroglial cells, incuba-
tionwith TNFα for 3 h induced A2B adenosine receptor desensitization
in a PKC-dependent manner [87], while longer incubations with TNFα
for up to 24 h reduced A2B adenosine receptor desensitization
[92]. These opposite changes also appear to be reﬂected in the
Fig. 6. Comparison of the predicted intracellular sequences of the rat and human A3
adenosine receptors (UniProtKB/Swiss-Prot accession numbers P28647 and P33765,
respectively). All serine and threonine residues are shown in bold, while potential
phosphorylation sites predicted by NetPhos (score N0.5) are also underlined. Thr318
(shown in red italic) in the COOH-terminus of the rat sequence was identiﬁed as a
crucial site for rapid regulation of the A3 adenosine receptor. The sequence in blue
italics is the YXXϕ motif, which in some receptors is known to interact with AP-2
protein in clathrin-coated pits. In addition, the YLLI motif in the human receptor is part
of a [D/E]XXLL motif, which is also associated with AP-2 interaction. The amino acids in
green italics show part of the predicted caveolin interaction domain present in the
human receptor, with the beginning of the sequence being just inside the 7th
transmembrane domain of the receptor. The full sequence is YAYKIKKF, which
corresponds to the caveolin interaction sequence ϕXϕXXXXϕ. The rat receptor does
not have a caveolin binding motif in this part of the receptor.
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TNFα enhancing A2B adenosine receptor phosphorylation in the short
term and reducing it in the long term [87,92]. However, since
treatment with TNFα also induced morphological changes in these
cells, it is possible that alterations in the relative levels or subcellular
location of various signalling components could in part explain these
opposite effects. Interestingly, PKC regulation of the A2B adenosine
receptor responsiveness may be of therapeutic importance in cardiac
disease. In ischemic preconditioning, short periods of ischemia and
reperfusion cause the heart to become resistant to infarction during
later episodes of ischemia/reperfusion [93]. The A2B adenosine
receptor is known to be crucial in mediating this effect [93], and a
recent study indicates that PKC activation greatly enhances the
sensitivity of the A2B adenosine receptor to adenosine in the heart
[94]. Thus, PKC-mediated sensitization of A2B receptors in the heart to
endogenous adenosine may underlie this effect [95,96], although the
exact molecular mechanism (e.g., receptor phosphorylation) under-
lying this important interaction has yet to be determined but deserves
further investigation.
Studies of A2B adenosine receptor trafﬁcking indicate that the
receptor undergoes internalization in an arrestin- , dynamin-, and
clathrin-dependent manner, [85,86,88,97]. Although both arrestin-2
and arrestin-3 are rapidly recruited to the plasma membrane
following agonist addition to HEK293 cells overexpressing the rat
A2B adenosine receptor, the kinetics of arrestin subtype interaction
with the receptor are different [98]. Thus, in cells engineered to
express low endogenous levels of arrestins, reintroduction of arrestin-
2 results in prolonged co-localisation of the receptor with arrestin-2
inside the cells and slow receptor recycling, whereas overexpression
of arrestin-3 results in much faster receptor recycling [98]. The
functional consequences of these variable arrestin interaction kinetics
deserve further study, particularly now that the diverse signalling
functions of arrestins have become apparent [13,14]. In addition, we
found that the distal COOH-terminus of the receptor is necessary for
arrestin-, dynamin-, and clathrin-dependent internalization of the
receptor; however, deletion of the terminus does not fully inhibit
desensitization and internalization but slows these regulatory
processes and converts them into an arrestin- and clathrin-indepen-
dent process which is still dynamin dependent [86,88]. The identity of
this alternative trafﬁcking pathway remains to be identiﬁed.
A PDZ (post synaptic density protein, Drosophila disc large tumor
suppressor, and zonula occludens-1 protein) ligand [19] is also found
at the extreme COOH-terminus of the A2B adenosine receptor. PDZ
domains are protein–protein recognition sequences that bind to
COOH-terminus ligand motifs that conform to type I (X-[S/T]-X-ϕ), II
(X-ϕ-X-ϕ), or III (x-[D/E]-X- ϕ) sequences, where X is any amino acid
and ϕ is a bulky hydrophobic residue. Thus, SLSL for the rat receptor
and GVGL for the human receptor are type II PDZ ligands (Fig. 5) [88].
Notably, the other adenosine receptor subtypes do not contain PDZ
ligand motifs at the COOH-termini (see Figs. 2, 3, and 6). The A2B
adenosine receptor has already been identiﬁed as a receptor that
interacts with NHERF proteins [99], which are PDZ domain-containing
proteins involved in a number of cellular functions including receptor
localization at the cell membrane. The presence of the PDZ ligand at
the COOH-terminus of the A2B adenosine receptor may facilitate
arrestin-dependent receptor regulation, and a receptor mutant
lacking this sequence internalizes slowly in an arrestin-independent
manner and unlike the wild-type receptor does not recycle signiﬁ-
cantly [88]. Furthermore, whereas NHERF1 co-immunoprecipitates
with wild-type A2B adenosine receptor, it does not do so with a
receptor deletion mutant with the PDZ ligand domain removed [88].
Together these results indicate that the distal COOH-terminus of the
A2B adenosine receptor is critical for the interaction of NHERF and
arrestins with the receptor. However, how these interactions are co-
ordinated is not clear and will require further study to shed light on
this intriguing interaction.The interaction between the A2B adenosine receptor and NHERF2
is of some importance in receptor trafﬁcking, signalling, and
desensitization in polarized epithelial cells [50,99,100]. In these
cells, adenosine stimulation recruits A2B adenosine receptors to the
cell surface via SNARE proteins [100] where the receptors are
stabilized in a complex with NHERF2 [99]. The latter binds to ezrin,
which interacts with the actin cytoskeleton and also with protein
kinase A, thus forming a localized signalling module. It is thus of
interest that not only does adenosine stimulation recruit A2B
adenosine receptors to the cell surface [99,100], but also eventually
desensitizes them [50].
3.4. A3 adenosine receptor desensitization and trafﬁcking
This adenosine receptor subtype is Gi coupled and undergoes rapid
agonist-induced desensitization and internalization [101–108], with
receptor phosphorylation also being observed, probably mediated by
GRKs [101,104]. In theCOOH-terminus of the rat receptor (Fig. 6), Thr318
and Thr319 in particular have been identiﬁed as key residues in A3
adenosine receptor regulation, possibly acting as phosphoacceptor sites
for GRKs [104]. There is also some evidence to suggest thatMAP kinases
may be involved in A3 adenosine receptor regulation, possibly by
regulating the association of GRK2 with the receptor [107], and indeed
A3 adenosine receptor activation does lead to MAP kinase activation in
cells [107]. Interestingly, if the COOH-terminus of the A1 adenosine
receptor is replaced by that of theA3 adenosine receptor, then the ability
of the hybrid receptor to redistribute non-visual arrestin in the cell
becomes more marked than that observed with the wild-type A1
adenosine receptor and in fact becomes similar to that observed with
the wild-type A3 adenosine receptor [103]. Together these results
suggest that the A3 adenosine receptor undergoes desensitization
following GRK-mediated phosphorylation of the distal COOH-terminus
of the receptor followed by arrestin binding to the phosphorylated
receptor. Following desensitization and internalization, the A3 adeno-
sine receptor undergoes recycling with resensitization of receptor
Table 1
Summary of adenosine receptor regulatory mechanisms.
Adenosine
receptor
subtype
Agonist-induced
phosphorylation
Agonist-induced
desensitization
Main mechanism/s
of internalization
Down-
regulation
A1 Rapid
phosphorylation
of tyrosine and
serine residues
reported in one
study; no
phosphorylation
detected in
another study
[39,42]
Arrestin
mediated?
Internalization
mediated? Rate
slow for some
responses, rapid
for others [29–
43]
Slow, via caveolae,
possibly also
clathrin-coated
pits [22,31,39,45–
47]
Arrestin
mediated
[40]
A2A Rapid,
extensive,
possibly
involves a
threonine
residue in the
proximal COOH-
terminus [57]
Rapid and
extensive in
some studies,
slow or modest
in others;
evidence for
GRK/arrestin
mechanism
[37,49,55–61]
Rapid and
extensive in some
studies, little
internalization
reported in others;
probably involves
arrestin
[48,49,66,70–72]
Yes [56]
A2B Not detectable
in one study,
reported on
threonine
residues in
others
[87,88,92]
Arrestin GRK
[58,59,85,91]
Arrestin, dynamin,
clathrin [86,88]
Not seen in
one study
but
receptor
targeted to
lysosomes
in another
[84,88]
A3 Rapid, extensive
[101,104]
GRK? Arrestin?
[101,103]
Arrestin?
[103,104]
Yes
[106,107]
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receptor also undergoes down-regulation [106,107]. However, contrary
to this classical view of A3 adenosine receptor regulation (see Fig 1),
agonist activation of endogenous A3 adenosine receptors in rat
basophilic leukemia-2H3 cells did not recruit non-visual arrestins to
clathrin-coated pits, under conditions where activation of other native
G-protein-coupled receptors in the cells did [109]. On the other hand,
the A3 adenosine receptor internalizes into transferrin-positive endo-
somes [43], suggestive of clathrin-dependent internalization, while
there aremotifs in theCOOH-terminus of this receptor (Fig. 6), including
theYXXϕmotif (whereX is any aminoacid andϕ is a bulkyhydrophobic
residue) and the [D/E]XXLLmotif, which are associatedwith interaction
with the AP-2 protein of clathrin-coated pits [19], again suggestive of
clathrin-mediated internalization. However, the arrestin, dynamin, and
clathrin dependence of A3 adenosine receptor regulation has not been
clearly demonstrated and leaves open the possibility that the receptor is
also able to trafﬁc by other pathways.
Recently the ability of a large series of ligands to induce inhibition
of cAMP formation as well as promoting arrestin recruitment has been
studied using the PathhunterTM system, which uses an enzyme
complementation assay as the basis for quantifying arrestin interac-
tion with the A3 adenosine receptor in intact cells [110]. Interestingly,
the rate of arrestin recruitment to the A3 adenosine receptor was
ligand dependent, while for some ligands the extent of arrestin
recruitment was not what would be predicted from the cAMP
inhibition data. For example, some ligands regarded as A3 adenosine
receptor antagonists, since they bound to the receptor but did not
inhibit cAMP formation, were in fact partial agonists in the arrestin
assay. These results strongly support the idea of arrestin-dependent
regulation of the A3 adenosine receptor but also suggest that the
arrestin-dependent regulation of the A3 adenosine receptor and
possibly the other adenosine receptor subtypes is ligand dependent,
as has been shown for other G-protein-coupled receptors [5]. This in
turn means that the ability of ligands to induce arrestin-dependent
desensitization, internalization, or signalling at A3 adenosine recep-
tors may not be directly related to their ability to couple to G-protein-
signalling pathways.
A ﬁnal interesting observation about A3 adenosine receptor
regulation pertains to their potential therapeutic use in rheumatoid
arthritis [3,4]; it has been found that administration of the anti-
rheumatoid drug methotrexate increases the expression of A3
adenosine receptors in inﬂamed tissues, therefore sensitizing the
cells to the anti-rheumatoid effect of A3 adenosine receptor agonists
[111]. The combined use of methotrexate and an A3 adenosine
receptor agonist is much more effective than either agent alone in
producing anti-inﬂammatory effects [111].
4. Concluding remarks
Although the agonist-dependent desensitization and trafﬁcking of
all four subtypes of adenosine receptor has been reported, a number
of factors need to be borne in mind when trying to draw overall
conclusions from these data:
• The possibility of species-dependent differences in regulation; for
example, the very different sequences at the distal COOH-termini of
the A2A adenosine receptor from different species (see Fig. 3) could
potentially lead to different mechanisms of regulation.
• The possibility of cell-context-dependent regulation of adenosine
receptor subtypes. This could occur because there are different con-
centrations of regulatory proteins such asGRKs/arrestins in distinct cell
types, or there may be large variations in receptor expression levels
that can alter the ability to detect desensitization under standard assay
conditions. In addition, receptors could also be located in different
subcellular compartments (e.g., lipid rafts/caveolae versus clathrin-
coatedpits [22], nerve terminals versus neuronal cell bodies [34], apicalversus basolateral membrane in polarized cells [50,99]), which could
also lead to different forms of regulation.
• The possibility of ligand-dependent regulation of receptor desensi-
tization and trafﬁcking, as shown for signalling and arrestin
recruitment for the A3 adenosine receptor [110]. This also raises
the intriguing question of whether and how arrestin-dependent
signalling pathways themselves might undergo desensitization. In
addition, almost nothing is known about the possible desensitiza-
tion of the less familiar signalling pathways triggered by adenosine
receptor activation [112].
• Our increasing knowledge of the range of G-protein-coupled
receptor-interacting proteins, other than G proteins, expands the
possibilities for receptor regulation outside of those described in the
classical model of G-protein-coupled receptor regulation. Examples
would include the interaction of α-actinin with the A2A adenosine
receptor [66] and the interaction of NHERF proteins with the A2B
adenosine receptor [88,99], and the ability of the A2A adenosine
receptor to form heterodimers or oligomers with the D2 dopamine
receptor [81].
Given these considerations, the main regulatory features of the
four adenosine receptor subtypes are summarized below in Table 1.
Apart from pharmacological considerations, the desensitization of
adenosine receptors is also of great physiological importance. Just
recently, it has been shown that adenosine-mediated desensitization
of adenosine receptors (A2A but also other subtypes) on T cells of the
immune system is a crucial factor in allowing these cells to respond
strongly to antigenic stimulation [113,114]. Adenosine normally
suppresses the immune response of these cells but adenosine receptor
desensitization releases them from inhibition for sufﬁcient time to
respond robustly to antigen challenge.
Finally, it is signiﬁcant that many of the studies of adenosine
receptor regulation described in this reviewwere carried out a decade
or more ago. Since then, a number of new technologies have appeared
1326 S. Mundell, E. Kelly / Biochimica et Biophysica Acta 1808 (2011) 1319–1328or become widely available, which would allow the mechanisms of
adenosine receptor regulation to be deﬁned, such as the use of siRNA
to selectively knockdown regulatory proteins such as GRKs or
arrestins [40], the availability of high throughput signalling assays
for multiple cell signalling pathways [110], the availability of mice
with the deletion or modiﬁcation of genes coding for regulatory
proteins [115], or the use of mass spectrometry to identify
phosphoacceptor sites in G-protein-coupled receptors [116]. The
priority must be to determine the regulatory mechanisms that
operate for endogenous adenosine receptors in relevant cell types
under physiological and pathological conditions. Furthermore, the
increasing availability of ligands with high afﬁnity and selectivity for
individual adenosine receptor subtypes should facilitate the required
further detailed study of endogenous receptor regulation.References
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